N
PRVL

Nuveen’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Nuveen’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-87,660
Closed -$1.1M – 3428
2020
Q4 		$1.1M Sell
87,660
-13,686
-14% -$173K ﹤0.01% 2771
2020
Q3 		$1.03M Buy
101,346
+37,727
+59% +$506K ﹤0.01% 2673
2020
Q2 		$948K Buy
63,619
+13,889
+28% +$214K ﹤0.01% 2639
2020
Q1 		$606K Buy
49,730
+31,899
+179% +$507K ﹤0.01% 2707
2019
Q4 		$282K Sell
17,831
-6,576
-27% -$83.9K ﹤0.01% 3025
2019
Q3 		$299K Buy
+24,407
New +$277K ﹤0.01% 3050

Nuveen's PRVL Position: Q1 2021 in Review

Nuveen sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 87,660 shares — an estimated $1.1M sold.

Nuveen first reported a position in PRVL in Q3 2019 and held it in 6 quarters. The position peaked at $1.1M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Nuveen reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Nuveen sold 87,660 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $1.1M.
  • Nuveen first reported a position in Prevail Therapeutics Inc. Common Stock in Q3 2019 and held it in 6 quarters.
  • Nuveen's Prevail Therapeutics Inc. Common Stock position peaked at $1.1M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Nuveen's 13F filing for Q1 2021, filed 17 May 2021.